HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer

Официальное название

MATCH-001: A Multicenter, Open-Label, Randomized Controlled Trial of Hepatic Arterial Infusion Chemotherapy Followed by Transarterial Chemoembolization Combined With Apatinib and Camrelizumab in Patients With Intermediate and Advanced Hepatocellular Carcinoma

Обзор

To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.

Вмешательства

• Процедура HTAC
  Patients will first undergo hepatic arterial infusion chemotherapy (HAIC) treatment. Subsequently, transarterial chemoembolization (TACE) will be administered sequentially following the completion of HAIC. This regimen will be combined with apatinib (a vascular endothelial growth factor receptor 2 \[VEGFR-2\] inhibitor) and camrelizumab (a programmed cell death protein 1 \[PD-1\] inhibitor) therapy.
• Процедура HAC
  Patients will receive a combination therapy consisting of HAIC, apatinib, and camrelizumab.
• Процедура TAC
  Patients will be treated with a regimen combining TACE, apatinib, and camrelizumab.

Первичные конечные точки

• Progression-Free Survival (PFS) [Assessed by mRECIST Criteria] [Срок оценки: Up to 27 months.]

Вторичные конечные точки (5)

• Objective Response Rate (ORR) [Assessed by mRECIST and RECIST Criteria] [Срок оценки: Up to 27 months]
• Disease Control Rate (DCR) [Assessed by mRECIST and RECIST Criteria] [Срок оценки: Up to 27 months]
• Duration of Response (DoR) [Assessed by RECIST and mRECIST Criteria] [Срок оценки: Up to 27 months]
• Overall Survival (OS) [Срок оценки: Up to 27 months]
• Progression-Free Survival (PFS) [Assessed by RECIST Criteria] [Срок оценки: Up to 27 months.]

Критерии участия

Критерии включения

• Age 18-80 years.
• Diagnosed with hepatocellular carcinoma (HCC) in accordance with the Standardization for Diagnosis and Treatment of Primary Hepatic Carcinoma (2024 Edition) issued by the National Health Commission of the People's Republic of China.
• BCLC stage B or C, with no indication or refusal of surgical treatment, and measurable lesions meeting the mRECIST (Modified Response Evaluation Criteria in Solid Tumors) criteria on baseline imaging.
• Child-Pugh liver function grade A or well-compensated grade B (score ≤7).
• ECOG Performance Status (PS) score 0-1.
• Expected survival time ≥12 weeks.

Критерии исключения

• Prior transarterial chemoembolization (TACE) or other local therapies for HCC (except bridging liver transplantation).
• Active viral hepatitis (hepatitis B or C) with pre-treatment viral load >100 IU/mL (positive for HCV RNA or HBV DNA) or without consistent antiviral therapy.
• Alcohol abuse or pregnancy.
• Concurrent other malignancies or history of other malignancies within the past 3 years.
• Renal dysfunction (creatinine \[Cr\] >2 mg/dL or creatinine clearance \[CCr\] <30 mL/min) or severe organic diseases of vital organs (heart, lung, brain, etc.).
• Inability to cooperate with interventional procedures.
• Presence of distant metastasis.
• Main portal vein tumor thrombus accompanied by impaired portal venous blood flow and collateral circulation.

Withdrawal Criteria

• Identification of non-compliance with the study protocol during the trial.
• Administration of radiotherapy or other interventions during the trial that prevent efficacy evaluation.
• Discontinuation of treatment due to severe adverse reactions (excluded from efficacy analysis but included in adverse reaction statistics).
• Patient or representative withdraws informed consent or requests to stop treatment.
• Loss to follow-up or death of the patient.

Key Terminology Notes

• National Health Commission of the People's Republic of China: Official English name of the Chinese health authority, consistent with government documentation.
• Standardization for Diagnosis and Treatment of Primary Hepatic Carcinoma (2024 Edition) : Translated title of the 2024 national guideline for HCC diagnosis and treatment, aligning with the 2022 edition's official English translation published in Cancer Research on Prevention and Treatment.
• mRECIST: Abbreviation for Modified Response Evaluation Criteria in Solid Tumors, the standard for assessing treatment response in HCC, widely used in clinical trials.
• BCLC Staging: Barcelona Clinic Liver Cancer staging system, a globally recognized framework for HCC prognosis and treatment decision-making.
• Child-Pugh Score: A widely used tool to assess liver function in patients with cirrhosis, with grades A (5-6 points), B (7-9 points), and C (10-15 points).
• ECOG PS Score: Eastern Cooperative Oncology Group Performance Status, a scale from 0 (fully active) to 5 (dead) used to evaluate a patient's ability to perform daily activities.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Простое слепое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07587034 · MATCH-001

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗